The restrictive emergency approval given to the Covid-19 vaccine developed by Bharat Biotech on January 3 has caused a sensation among many experts who have questioned the government's decision. Bharat Biotech has applied for permission to obtain its vaccine, Covaxin, a complete inactivated vaccine against the Virion coronavirus that it has developed in collaboration with the Indian Council for Medical Research (ICMR) and the National Institute of Virology (NIV) in Pune.
Approval was restricted and conditional on Union Health Minister Harsh Vardan announcing that those receiving Covaxin injections would be monitored in the same way as volunteers in clinical trials. Several industry experts expressed surprise at the decision, pointing that Covaxin clinical trial data had not been released.
While the science of vaccine development is global, the regulatory procedure for their use and licensing varies from country to country. In India, clinical trials and approval of new drugs, including vaccines, are subject to the New Drugs and Clinical Trials Rules that were notified in March 2019.
Under normal circumstances, vaccine approval follows these steps:
Phase IV human clinical trials refer to post-marketing surveillance studies, the data of which is analyzed for long-term decision making.
A key aspect of granting approval for a vaccine or medicine in India is the requirements for clinical trials to take place in the country, from stage I to stage III.
This term is not used in the 2019 Indian vaccine approval rules. This term became popular after its use in the United States. However, the Indian Rules have a window for "expedited approval" in "special situations". The current Covid-19 pandemic is one of those special cases.
The 2019 rules state that “an expedited approval for a new drug [read the vaccine] may also be granted if it is intended to treat a serious or life-threatening condition or a country-specific related disease, and treats medical conditions that have not to compliment.
There is another special requirement for rapid approval of the vaccine if the results of the second phase shows "significant efficacy".
Here's what the 2019 rules say: "If the observed efficacy of a specific dose is observed in the second phase of clinical trials of a new experimental drug in meeting the unmet medical needs of a serious and life-threatening disease in the country, then the case can be considered for marketing approval by the Central licensing authority based on data from phase II clinical trials. "
The final authority for granting approval for a vaccine or other drug rests with the CDSCO. It is chaired by the Drug Controller General of India (DCGI). CDSCO operates under the Union Ministry of Health and Family Welfare.
On January 3, DCGI issued a statement saying that Covaxin "has been developed on the Vero cell platform, which has a proven track record of safety and efficacy in the country and around the world."
DCGI said Covaxin developer Bharat Biotech has shared "safety and immunity data" from its animal trials, including "challenge studies in non-human primates (Rhesus macaques) and hamsters" with drug regulator CSDSCO.
Regarding clinical trials in humans, DCGI said phases I and II "have shown that the vaccine is safe and provides a strong immune response." Citing phase 3 data from some 22,500 participants, the drug regulator said: "It has been discovered to be safe as per the data available till date.
Also Read: Steps to take to make sure your money, investments are available and accessible when needed